Substance-related disorder

Youturn Health Announces Partnership with Sure Med to Offer Education and Support for Behavioral Health and Substance Misuse

Retrieved on: 
Giovedì, Novembre 3, 2022
EPRO, Program, Risk, Substance-related disorder, CEO, MED, Health, CDC, Health literacy, Fentanyl, Patient, Centers for Disease Control and Prevention, Compliance, Drug overdose, AL, Suicidal ideation, Center, Partnership, Pain management, Multimedia, Grief, Medical device, Medicine, Pharmaceutical industry

Patients of Sure Med's Perspectives in Care program will now have access to Youturn Health's virtual support program.

Key Points: 
  • Patients of Sure Med's Perspectives in Care program will now have access to Youturn Health's virtual support program.
  • Nonmedical use of opioids and opioid analogs such as illegally manufactured fentanyl has soared in recent years, causing a nationwide health crisis.
  • Our partnership with Youturn Health ensures that all patients have access to best-in-class education and coaching, underscoring our commitment to ending the overdose epidemic."
  • Based in Mobile, AL, Sure Med Compliance is a healthcare technology company, dedicated to creating safer exposures to controlled substances.

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

Retrieved on: 
Martedì, Novembre 1, 2022
Chemicals, Plastics, FDA, Health, Manufacturing, Pharmaceutical, Biotechnology, API, DMF, Methylnaltrexone, LLC, Chemistry, CDMO, Substance-related disorder, Regulation of tobacco by the U.S. Food and Drug Administration, View, Patent, Attention deficit hyperactivity disorder management, Cannabinoid, Pain management, FDA, Active ingredient, Patient, Food, Opioid, OIC, Quality of life, Chronic pain, Pharmaceutical industry, Fine chemical, Johnson & Johnson

Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.

Key Points: 
  • Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.
  • Methylnaltrexone bromide is the active ingredient in Relistor, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.
  • Methylnaltrexone bromide is a significant advancement, providing relief for these patients who need to manage chronic pain with opioids.
  • Noramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.

CVS Health reaches agreement in principle for global opioid settlement

Retrieved on: 
Mercoledì, Novembre 2, 2022
Heart, Annual report, Pharmacist, Risk, Pharmacy, Health, NYSE, CVS Pharmacy, City, Physician, Substance-related disorder, CVS Health, Technology, Nursing, Investment, General counsel, Social media, CVS, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Conditional sentence, Practitioner, Opioid, Parent, Insurance, Pharmaceutical industry

CVS Health will continue to defend against any litigation that the final agreement does not resolve.

Key Points: 
  • CVS Health will continue to defend against any litigation that the final agreement does not resolve.
  • CVS Health has undertaken numerous initiatives to fight opioid abuse, which include:
    Significant investments in technology and procedures to support its pharmacists in exercising their professional obligations.
  • The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health.
  • CVS Health is the leading health solutions company, delivering care like no one else can.

SK pharmteco appoints Joerg Ahlgrimm as CEO

Retrieved on: 
Martedì, Novembre 1, 2022
API, Growth, Plasma, Board of directors, CEO, Telecommunication, CMOS, Leadership, Semiconductor, Center, CGMP, Board, Industry, CGT, Plant, CDMO, Substance-related disorder, Cell, View, Collection, Baxter International, Gene, Technology, 2009 Davis Cup, EV, SK Group, Director, Multimedia, Baxalta, Isolde Ahlgrimm, CBM, Management, Renewable energy, Fine chemical

"I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.

Key Points: 
  • "I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.
  • His leadership was retained by SK Inc. when it acquired AMPAC Fine Chemicals in 2018 and established SK pharmteco in 2019.
  • Headquartered in Sacramento, California, SK pharmteco is a global CDMO and a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea's second-largest conglomerate.
  • SK pharmteco is the single customer-facing team comprised of SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea, Yposkesi and most recently The Center for Breakthrough Medicines.

SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation

Retrieved on: 
Martedì, Novembre 1, 2022
API, Growth, Plasma, Board of directors, CEO, CMOS, Leadership, Center, CGMP, Board, Industry, COVID-19, CGT, Plant, CDMO, KRW, Substance-related disorder, Cell, Collection, Baxter International, Gene, Technology, 2009 Davis Cup, SK Group, Director, Baxalta, Isolde Ahlgrimm, CBM, Diabetes, Management, Fine chemical, Synthetic rubber

FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- SK pharmteco, a global contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, today announced that Joerg Ahlgrimm will be appointed as the Chief Executive Officer. Ahlgrimm will assume the global leadership of the company and spearhead its next phase of innovation and global growth.

Key Points: 
  • Ahlgrimm will assume the global leadership of the company and spearhead its next phase of innovation and global growth.
  • "I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.
  • I strongly believe Joerg will successfully lead SK pharmteco to its next phase of growth," said Dr. Malik.
  • SK pharmteco is a portfolio company of SK Inc. (South Korea) and serves as a strategic part of SK's growing pharmaceutical sector.

UnitedRx Combats Drug Diversion in Healthcare with New Solution, Cubex®

Retrieved on: 
Martedì, Novembre 1, 2022
American Securities, Culture, CEO, American Nurses Association, Marketing, Pharmacy, Intermediate Care Facilities for Individuals with Mental Retardation, Substance-related disorder, Hospice, Group, Amphetamine, Technology, Nursing, Patient, Bed, Association, Solution, Health insurance, Medicine, Pharmaceutical industry, I-CubeX

HILLSIDE, Ill., Nov. 1, 2022 /PRNewswire-PRWeb/ -- UnitedRx, the Midwest's largest full-service, independent long-term care pharmacy, is combating drug diversion in skilled nursing facilities with cutting-edge technology such as Cubex®. To ensure that controlled substances are secure, accounted for, and always administered at the correct dosage, the medicine cabinet features extra security and automated logging.

Key Points: 
  • HILLSIDE, Ill., Nov. 1, 2022 /PRNewswire-PRWeb/ -- UnitedRx , the Midwest's largest full-service, independent long-term care pharmacy, is combating drug diversion in skilled nursing facilities with cutting-edge technology such as Cubex.
  • With over 3 million nurses employed in the healthcare industry, this translates to an estimated 300,000 substance abusers.
  • Drugs that may go unnoticed for a long time are also frequently accessible to healthcare practitioners, further adding to the problem of drug diversion among nurses and CNAs.
  • The device, which is used as part of a complete diversion prevention and detection program, prohibits multiple access to drugs.

Drug Enforcement Administration (DEA) Controlled Substances Module and Handbook 2022: Guide to Manufacturing, Storing, Securing, Shipping, Distributing, Importing, Exporting and Disposal - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Ottobre 31, 2022
FDA, Pharmaceutical, Health, DEA, Directory, Controlled Substances Act, Substance-related disorder, Handbook, Pharmacy, Electronic prescribing, Gum arabic, Drug

The "Controlled Substances Module and Handbook" directory has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Controlled Substances Module and Handbook" directory has been added to ResearchAndMarkets.com's offering.
  • You need easy-to-understand text that clarifies what each regulation under the Controlled Substances Act requires.
  • The Controlled Substances Handbook describes in plain English detailed Drug Enforcement Administration (DEA) requirements for manufacturing, storing, securing, shipping, distributing, importing, exporting and disposing of controlled substances as well as evolving requirements for electronic prescribing and online pharmacies.

Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa

Retrieved on: 
Giovedì, Ottobre 27, 2022
Quality control, API, Substance-related disorder, CDMO, Tablet, Research, CEO, St. Paul Airport, Fine chemical, Cambrex Corporation

Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex's flagship facility in Charles City, Iowa.

Key Points: 
  • Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex's flagship facility in Charles City, Iowa.
  • Cambrex is expected to add approximately 40 new jobs over the next 2-3 years at the new site in Minneapolis.
  • Cambrex will simultaneously launch a multi-phase, 9,000-square-foot expansion and 21,000-square-foot renovation project in Charles City, Iowa.
  • The expansion will add a new quality control laboratory and administrative office space, which will bring 40 new jobs at the site.

Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa

Retrieved on: 
Giovedì, Ottobre 27, 2022
Quality control, API, Substance-related disorder, CDMO, Tablet, Research, CEO, St. Paul Airport, Fine chemical, Cambrex Corporation

Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex's flagship facility in Charles City, Iowa.

Key Points: 
  • Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex's flagship facility in Charles City, Iowa.
  • Cambrex is expected to add approximately 40 new jobs over the next 2-3 years at the new site in Minneapolis.
  • Cambrex will simultaneously launch a multi-phase, 9,000-square-foot expansion and 21,000-square-foot renovation project in Charles City, Iowa.
  • The expansion will add a new quality control laboratory and administrative office space, which will bring 40 new jobs at the site.

Constellation Brands Announces Plan to Convert Common Stock Holding in Canopy Growth

Retrieved on: 
Martedì, Ottobre 25, 2022
Constellation, Maker, News, Time, Bangladesh Securities and Exchange Commission, Sale, Removal of cannabis from Schedule I of the Controlled Substances Act, Webcast, Constellation Brands, Wine, Grupo Modelo, NYSE, Annual report, Income, Transaction, Warrant, Indian stock exchange, Love, Security (finance), Investment, Canopy Growth, Exercise, Board, CEO, CPG, Corona (beer), Intention, Beer, EDT, Consent, Amendment, GLOBE, Controlled Substances Act, Disclosure, Ownership, Substance-related disorder, SEDAR, CBG, Drug, Cryptocurrency, Bookkeeping, Note, Canopy

Canopy only holds non-voting and non-participating exchangeable shares of Canopy USA which are convertible into common shares of Canopy USA.

Key Points: 
  • Canopy only holds non-voting and non-participating exchangeable shares of Canopy USA which are convertible into common shares of Canopy USA.
  • Greenstar and CBG have entered into a voting support agreement with Canopy to vote in favor of the Amendment.
  • Accordingly, for early warning reporting purposes, Constellation will be deemed to beneficially own the Common Shares issuable on conversion of the Exchangeable Shares.
  • Constellation disclaims any responsibility for all disclosure issued by Canopy and any commentary made by Canopy on its webcast.